Clinical Trial

Eosinopenia in Severe COPD Exacerbation

Study acronym: A-TREC

Recruiting

Record status

This record was last updated April 14, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Summary

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia. The main aims of the study are to: 1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2024-01-02; most recent amendment 2026-04-13.

Status change: Not Yet Recruiting → Recruiting 2024-01-25

Trial Details

NCT Number	NCT06188065
Lead Sponsor	Northumbria Healthcare NHS Foundation Trust Collaborators: Newcastle University, Chiesi UK, GlaxoSmithKline
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	200 participants
Start Date	2024-01-22
Primary Completion	2026-07 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-14